JP2019504821A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504821A5
JP2019504821A5 JP2018526219A JP2018526219A JP2019504821A5 JP 2019504821 A5 JP2019504821 A5 JP 2019504821A5 JP 2018526219 A JP2018526219 A JP 2018526219A JP 2018526219 A JP2018526219 A JP 2018526219A JP 2019504821 A5 JP2019504821 A5 JP 2019504821A5
Authority
JP
Japan
Prior art keywords
dihydro
methyl
benzyl
alkyl
purin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018526219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504821A (ja
JP6964343B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/062837 external-priority patent/WO2017087837A1/en
Publication of JP2019504821A publication Critical patent/JP2019504821A/ja
Publication of JP2019504821A5 publication Critical patent/JP2019504821A5/ja
Priority to JP2021077708A priority Critical patent/JP7273886B2/ja
Application granted granted Critical
Publication of JP6964343B2 publication Critical patent/JP6964343B2/ja
Priority to JP2022178945A priority patent/JP7650854B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018526219A 2015-11-20 2016-11-18 ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン Active JP6964343B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021077708A JP7273886B2 (ja) 2015-11-20 2021-04-30 ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン
JP2022178945A JP7650854B2 (ja) 2015-11-20 2022-11-08 ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258162P 2015-11-20 2015-11-20
US62/258,162 2015-11-20
PCT/US2016/062837 WO2017087837A1 (en) 2015-11-20 2016-11-18 Purinones as ubiquitin-specific protease 1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021077708A Division JP7273886B2 (ja) 2015-11-20 2021-04-30 ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン

Publications (3)

Publication Number Publication Date
JP2019504821A JP2019504821A (ja) 2019-02-21
JP2019504821A5 true JP2019504821A5 (enExample) 2019-12-26
JP6964343B2 JP6964343B2 (ja) 2021-11-10

Family

ID=57472109

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018526219A Active JP6964343B2 (ja) 2015-11-20 2016-11-18 ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン
JP2021077708A Active JP7273886B2 (ja) 2015-11-20 2021-04-30 ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン
JP2022178945A Active JP7650854B2 (ja) 2015-11-20 2022-11-08 ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021077708A Active JP7273886B2 (ja) 2015-11-20 2021-04-30 ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン
JP2022178945A Active JP7650854B2 (ja) 2015-11-20 2022-11-08 ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン

Country Status (13)

Country Link
US (4) US10189841B2 (enExample)
EP (2) EP3377493B1 (enExample)
JP (3) JP6964343B2 (enExample)
KR (1) KR102708936B1 (enExample)
CN (2) CN108473495B (enExample)
AU (3) AU2016356694B2 (enExample)
BR (1) BR112018010216B1 (enExample)
CA (1) CA3005353A1 (enExample)
IL (3) IL300788A (enExample)
MX (2) MX2021001186A (enExample)
RU (1) RU2750151C2 (enExample)
SG (1) SG11201804098TA (enExample)
WO (1) WO2017087837A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2750151C2 (ru) 2015-11-20 2021-06-22 Форма Терапьютикс, Инк. Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1
ES3040707T3 (en) 2017-11-01 2025-11-04 Dana Farber Cancer Inst Inc Usp1 or uaf1 inhibitors for use in treating cancer
JP7301042B2 (ja) 2018-03-30 2023-06-30 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
CA3108676A1 (en) * 2018-08-09 2020-02-13 David J. Guerin Carboxamides as ubiquitin-specific protease inhibitors
CN109503421B (zh) * 2018-11-20 2022-10-14 黎明化工研究设计院有限责任公司 一种提高叠氮胺燃料合成过程安全性的方法
IL284050B2 (en) 2018-12-20 2026-01-01 Ksq Therapeutics Inc Modified pyrazolopyrimidines and modified purines and their use as 1 uso inhibitors
CN113474346B (zh) * 2018-12-28 2024-12-27 福马治疗有限公司 用于抑制泛素特异性蛋白酶1的组合物
EP3976602A4 (en) * 2019-05-31 2023-05-31 Chong Kun Dang Pharmaceutical Corp. 1,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE-6 INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF
AU2020284167B2 (en) * 2019-05-31 2023-05-11 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
CN110759902B (zh) * 2019-11-01 2022-04-22 海南一龄医疗产业发展有限公司 Set8赖氨酸甲基转移酶抑制剂及其制备方法和用途
US20230183215A1 (en) * 2020-05-21 2023-06-15 Stemsynergy Therapeutics, Inc. Notch Inhibitors and Uses Thereof
US20230219965A1 (en) * 2020-06-02 2023-07-13 KSQ Therapeutics, Inc. Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors
KR102458689B1 (ko) * 2020-07-08 2022-10-25 원광대학교산학협력단 피페리딘 화합물 및 이의 제조 방법
KR102685058B1 (ko) * 2020-09-02 2024-07-15 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물
CN111926018B (zh) * 2020-09-04 2022-07-12 首都医科大学附属北京儿童医院 降低usp1表达的物质在制备治疗儿童t系急性淋巴细胞白血病的药物中的应用
KR20230098186A (ko) 2020-10-30 2023-07-03 케이에스큐 세러퓨틱스 인코포레이티드 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도
BR112023018799A2 (pt) * 2021-03-17 2023-12-12 Medivir Ab Derivados de purina como agentes anticâncer
WO2022199547A1 (zh) * 2021-03-22 2022-09-29 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
MX2023011709A (es) * 2021-04-07 2023-10-12 Forma Therapeutics Inc Inhibidor de la proteasa 1 especifica de ubiquitina (usp1).
TW202304933A (zh) * 2021-04-09 2023-02-01 大陸商海南耀臻生物醫藥科技有限公司 泛素特異性蛋白酶1(usp1)抑制劑、藥物組合物及其治療哺乳動物由usp1介導的疾病的方法
CN117412973A (zh) * 2021-05-31 2024-01-16 上海瑛派药业有限公司 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用
WO2023069959A1 (en) * 2021-10-18 2023-04-27 Dana-Farber Cancer Institute, Inc. Covalent egfr inhibitors and methods of use thereof
EP4429770A1 (en) * 2021-11-10 2024-09-18 Biogen MA Inc. Btk inhibitors
WO2023083286A1 (en) 2021-11-12 2023-05-19 Insilico Medicine Ip Limited Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
MX2024005756A (es) * 2021-11-12 2024-09-06 Insilico Medicine Ip Ltd Inhibidores de molecula peque?a de la proteasa 1 especifica de ubiquitina (usp1) y usos de los mismos.
PE20241234A1 (es) * 2021-11-12 2024-06-19 Insilico Medicine Ip Ltd Inhibidores de molecula pequena de proteasa especifica de ubiquitina 1 (usp1) y usos de los mismos
WO2023148643A1 (en) * 2022-02-03 2023-08-10 Aurigene Oncology Limited Fused bicyclic heterocyclyl compounds as usp1 inhibitors
WO2023208130A1 (zh) * 2022-04-29 2023-11-02 江苏亚虹医药科技股份有限公司 嘧啶类化合物、其制备方法及其医药用途
EP4543890A1 (en) * 2022-06-23 2025-04-30 Forma Therapeutics, Inc. Usp1 inhibitors and uses thereof
CA3259938A1 (en) * 2022-06-29 2024-01-04 Zentaur Therapeutics Usa Inc. USP1 INHIBITORS AND RELATED USES
WO2024022266A1 (en) * 2022-07-25 2024-02-01 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heteroaryl compounds as inhibitors of usp1
WO2024022519A1 (zh) * 2022-07-28 2024-02-01 先声再明医药有限公司 杂环并嘧啶类化合物及其应用
CN119790043A (zh) * 2022-08-26 2025-04-08 海南先声再明医药股份有限公司 三环类化合物及其应用
WO2024051795A1 (zh) * 2022-09-09 2024-03-14 正大天晴药业集团股份有限公司 用作泛素-特异性蛋白酶抑制剂的取代嘌呤酮衍生物
IL319492A (en) * 2022-09-20 2025-05-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A carbonyl-fused heterocyclic derivative that acts as a ubiquitin-specific protease
WO2024078436A1 (zh) * 2022-10-09 2024-04-18 海南先声再明医药股份有限公司 杂环并嘧啶类化合物、药物组合物及其应用
EP4605391A1 (en) 2022-10-21 2025-08-27 Exelixis, Inc. 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors
WO2024153175A1 (en) 2023-01-19 2024-07-25 Laekna Therapeutics Shanghai Co., Ltd. Heteroaromatic compounds and their use as usp1 inhibitors
TW202509030A (zh) 2023-05-08 2025-03-01 美商譚格醫療公司 化合物及使用方法
WO2024233665A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
CN116621846B (zh) * 2023-07-24 2023-10-17 华润医药研究院(深圳)有限公司 双环杂环及三环杂环类化合物及其制备方法和医药用途
TW202530229A (zh) * 2023-09-26 2025-08-01 大陸商上海濟煜醫藥科技有限公司 氮雜環胺類化合物作為泛素-特異性蛋白酶1抑制劑的製備方法、應用及其用途
WO2025102016A1 (en) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
WO2025151705A1 (en) 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway
CN119707772B (zh) * 2024-12-23 2025-09-02 浙江大学 一种usp14共价抑制剂及其制备方法和应用

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440929A (en) 1981-07-16 1984-04-03 Usv Pharmaceutical Corporation Imidazoquinoxaline compounds
DK476885D0 (da) 1985-10-17 1985-10-17 Ferrosan As Heterocycliske forbindelser og fremgangsmaader til fremstilling heraf
US4859672A (en) 1986-10-29 1989-08-22 Rorer Pharmaceutical Corporation Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone
JPS63199347A (ja) 1987-02-14 1988-08-17 Konica Corp 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
IL90315A0 (en) 1988-06-01 1989-12-15 Ferrosan As Imidazoquinoxaline compounds,their preparation and pharmaceutical compositions containing them
DK626288D0 (da) 1988-11-10 1988-11-10 Ferrosan As Kemisk proces til fremstilling af imidazoquinoxaliner og mellemprodukter til brug i processen
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
DK588489D0 (da) 1989-11-22 1989-11-22 Ferrosan As Heterocykliske forbindelser, deres fremstilling og anvendelse
CA2110942A1 (en) 1991-06-14 1992-12-23 Pharmacia & Upjohn Company Llc Imidazo¬1,5-a|quinoxalines
WO1993012113A1 (en) 1991-12-17 1993-06-24 The Upjohn Company 3-SUBSTITUTED IMIDAZO (1,5-a) AND IMIDAZO (1,5-a)-TRIAZOLO (1,5-c) QUINOXALINES AND QUINAZOLINES WITH CNS ACTIVITY
WO1993017025A1 (en) 1992-02-19 1993-09-02 The Upjohn Company 3-substituted imidazo(1,5-a)quinoxalines and quinazolines with cns activity
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
GB9226879D0 (en) 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
US5516774A (en) 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5521173A (en) 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
WO1999024432A1 (fr) 1997-11-12 1999-05-20 Mitsubishi Chemical Corporation Derives de purine et medicament les renfermant en tant qu'ingredient actif
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
TW572758B (en) * 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
JP3814125B2 (ja) 1999-06-02 2006-08-23 大日本住友製薬株式会社 2−アリール−8−オキソジヒドロプリン誘導体からなる医薬
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
JP3675274B2 (ja) 2000-01-27 2005-07-27 ダイソー株式会社 9−(2−ヒドロキシアルキル)プリン誘導体および1−(2−ヒドロキシアルキル)ピリミジン誘導体の製造法
US20020128264A1 (en) 2000-07-07 2002-09-12 Taylor Eve M. Methods for treatment of conditions affected by activity of multidrug transporters
US20020040031A1 (en) 2000-07-07 2002-04-04 Glasky Michelle S. Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
EP1790344B1 (en) 2000-07-07 2011-02-23 Spectrum Pharmaceuticals, Inc. Methods for treatment of disease-induced peripheral neuropathy and related conditions
US20020040032A1 (en) 2000-07-07 2002-04-04 Glasky Michelle S. Methods for stimulation of synthesis of synaptophysin in the central nervous system
US20020091133A1 (en) 2000-12-12 2002-07-11 Eve M. Taylor Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis
US6960595B2 (en) 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
US20020156277A1 (en) 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
AU2003211993A1 (en) 2002-02-15 2003-09-04 Kyowa Hakko Kogyo Co., Ltd. (1,2,4)TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVES
EP1485395A4 (en) 2002-02-28 2011-04-13 Biota Scient Management NUCLEOTIDE MIMETICS AND PRODRUGS THEREOF
US7247621B2 (en) 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
DK1537114T3 (da) 2002-08-07 2006-11-13 Novartis Ag Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande
US7371857B2 (en) 2002-08-08 2008-05-13 Valeant Research & Development Synthesis for hydroxyalkylated heterocyclic bases
AU2003294249A1 (en) 2002-11-08 2004-06-03 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
JP2004217582A (ja) 2003-01-16 2004-08-05 Abbott Japan Co Ltd 9h−プリン誘導体
US20040180898A1 (en) 2003-03-03 2004-09-16 Bang-Chi Chen Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines
CN1845908A (zh) 2003-07-02 2006-10-11 弗·哈夫曼-拉罗切有限公司 5-取代的喹唑啉酮衍生物
BRPI0412868A (pt) 2003-07-23 2006-10-03 Wyeth Corp compostos de sulfonildihidroimidazopiridinona como ligantes da 5-hidroxitriptamina-6
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
CA2552664A1 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
AU2005214380A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
CA2566436C (en) 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
JP2008500338A (ja) 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び/又は予防する方法
EP1750715A1 (en) 2004-06-04 2007-02-14 Icos Corporation Methods for treating mast cell disorders
WO2006044504A1 (en) 2004-10-13 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
AU2006210422B2 (en) 2005-02-04 2012-09-13 Takeda Pharmaceutical Company Limited Inhibitors of E1 activating enzymes
EP1885356A2 (en) 2005-02-17 2008-02-13 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
KR20080013886A (ko) 2005-04-05 2008-02-13 파마코페이아, 인코포레이티드 면역억제용 퓨린 및 이미다조피리딘 유도체
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US20090023723A1 (en) 2005-09-21 2009-01-22 Pharmacopeia Drug Discovery, Inc. Purinone derivatives for treating neurodegenerative diseases
DE102005062987A1 (de) 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
US7989459B2 (en) 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CN101448832A (zh) 2006-05-26 2009-06-03 诺瓦提斯公司 醛固酮合酶和/或11β-羟化酶抑制剂
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
WO2007149484A2 (en) 2006-06-20 2007-12-27 Dana-Farber Cancer Institute Inhibitors of usp1 deubiquitinating enzyme complex
WO2008030744A2 (en) * 2006-09-05 2008-03-13 Board Of Regents, The University Of Texas System Inhibitors of c-met and uses thereof
EP2471529A3 (en) * 2006-09-05 2012-10-10 Emory University Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof
WO2008045529A1 (en) 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
MX2009004019A (es) * 2006-10-19 2009-06-19 Signal Pharm Llc Compuestos heteroarilo, composiciones de los mismos, y uso de los mismos como inhibidores de proteina cinasa.
CA2669686A1 (en) 2006-11-16 2008-05-22 Pharmacopeia, Llc 7-substituted purine derivatives for immunosuppression
US20080119496A1 (en) 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
EP2132207A2 (en) 2007-03-23 2009-12-16 Amgen Inc. Heterocyclic compounds and their uses
WO2008117796A1 (ja) 2007-03-28 2008-10-02 Dainippon Sumitomo Pharma Co., Ltd. 新規ムチリン誘導体
US20090182035A1 (en) 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
MX2009010946A (es) 2007-04-11 2009-10-29 Alcon Res Ltd Uso de un inhibidor del factor de necrosis tumoral alfa mas una antihistamina para tratar rinitis alergica y conjuntivitis alergica.
GB0708258D0 (en) 2007-04-27 2007-06-06 Katholleke Universiteit Leuven New anti-viral nulceoside analogs
WO2008131501A2 (en) 2007-04-27 2008-11-06 Katholieke Universiteit Leuven New anti-viral nucleoside analogs
WO2008143674A1 (en) 2007-05-23 2008-11-27 Pharmacopeia, Inc. Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
KR20100023907A (ko) 2007-06-26 2010-03-04 사노피-아벤티스 벤즈이미다졸 및 아자벤즈이미다졸의 위치선택적 구리 촉매화 합성
JP2009007273A (ja) 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
US20090118301A1 (en) 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
AU2008326784B2 (en) 2007-11-20 2014-04-24 Merck Sharp & Dohme Corp. Non-nucleoside reverse transcriptase inhibitors
US20090143392A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Methods of Treating Obesity and Metabolic Disorders
AU2008329072A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-A) pyrazines as inhibitors of phosphodiesterase 10
US7875618B2 (en) 2007-11-30 2011-01-25 Wyeth Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders
JP2011509962A (ja) 2008-01-17 2011-03-31 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換スルホンアミド誘導体
EP2229395A1 (en) 2008-01-17 2010-09-22 Grünenthal GmbH Substituted sulfonamide derivatives
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
CA2716921A1 (en) 2008-03-21 2009-09-24 Merck Sharp & Dohme Corp. Quinolizidinone m1 receptor positive allosteric modulators
WO2009129120A2 (en) 2008-04-15 2009-10-22 Rfs Pharma, Llc Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
US20110288070A1 (en) 2008-05-05 2011-11-24 ROGERS Kathryn Methods for treating cognitive disorders using inhibitors of histone deacetylase
CN102131810B (zh) 2008-06-25 2014-02-26 百时美施贵宝公司 作为抗hiv剂的二酮稠合的吡咯并哌啶类和吡咯并哌嗪类
US9062056B2 (en) 2008-09-09 2015-06-23 Boehringer Ingelheim International Gmbh Aza-benzimidazolone Chymase inhibitors
JP5539989B2 (ja) 2008-09-16 2014-07-02 プロキシマジェン エルティーディー 新規化合物i
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
US8835422B2 (en) 2008-12-11 2014-09-16 Cara Therapeutics, Inc. Substituted imidazoheterocycle derivatives
CN101824036A (zh) 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
PL2493895T3 (pl) 2009-10-29 2017-10-31 Vectura Ltd Zawierające azot (N) heteroarylowe pochodne jako inhibitory kinazy JAK3
JP2011136925A (ja) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
PH12012501581A1 (en) 2010-02-03 2012-10-22 Signal Pharm Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
WO2011137320A2 (en) 2010-04-30 2011-11-03 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of usp1 deubiquitinating enzyme activity
WO2011156889A1 (en) 2010-06-14 2011-12-22 Trt Pharma Inc. Novel modulators of nrf2 and uses thereof
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
JP2012012332A (ja) 2010-06-30 2012-01-19 Dainippon Sumitomo Pharma Co Ltd 新規アザインドール誘導体
WO2012003576A1 (en) 2010-07-06 2012-01-12 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
CN102485721B (zh) 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI541241B (zh) 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
JP5990106B2 (ja) 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
JP5995956B2 (ja) 2011-03-26 2016-09-21 フォルム ファーマシューティカルズ、インコーポレイテッド 前頭側頭葉変性症の標的治療の方法
JP2014513071A (ja) 2011-04-04 2014-05-29 シエナ ビオテク ソシエタ ペル アチオニ ウィント経路遮断薬
WO2013025628A1 (en) 2011-08-15 2013-02-21 Ligand Pharmaceuticals Incorporated Janus kinase inhibitor compounds and methods
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
EP3466423B1 (en) 2011-10-19 2021-07-28 Signal Pharmaceuticals, LLC Treatment of cancer with tor kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
KR102064626B1 (ko) 2012-02-24 2020-01-09 시그날 파마소티칼 엘엘씨 Tor 키나제 억제자 복합 치료법을 사용한 비소세포 폐암의 치료 방법
WO2013134079A1 (en) 2012-03-05 2013-09-12 Amgen Inc. Oxazolidinone compounds and derivatives thereof
US9338896B2 (en) 2012-07-25 2016-05-10 Enthone, Inc. Adhesion promotion in printed circuit boards
US9566310B2 (en) 2012-09-10 2017-02-14 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
US20150246888A1 (en) 2012-09-11 2015-09-03 Michael Johnson Enoyl reductase inhibitors with antibacterial activity
AU2013202768B2 (en) * 2012-10-18 2015-11-05 Signal Pharmaceuticals, Llc Treatment of cancer with TOR kinase inhibitors
EP2938610A2 (en) * 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
JP6024979B2 (ja) 2013-02-21 2016-11-16 学校法人金沢工業大学 難燃組成物、それを用いた難燃化処理方法および難燃材料
CN103923085B (zh) 2013-02-25 2016-08-24 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的吡啶杂环化合物及其用途
CA2902858A1 (en) 2013-02-28 2014-09-04 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
US9187454B2 (en) 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
EP2970200A1 (en) 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
TW201446768A (zh) 2013-03-15 2014-12-16 Biogen Idec Inc S1p及/或atx調節劑
WO2014160592A2 (en) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
SG11201510409QA (en) 2013-06-21 2016-01-28 Zenith Epigenetics Corp Novel bicyclic bromodomain inhibitors
WO2015200677A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CN106467538B (zh) 2015-08-14 2019-03-05 沈阳中化农药化工研发有限公司 一种取代的四氢异喹啉化合物与用途
RU2750151C2 (ru) 2015-11-20 2021-06-22 Форма Терапьютикс, Инк. Гипоксантины в качестве ингибиторов убиквитин-специфической протеазы 1
CN107629057B (zh) 2016-07-19 2020-03-27 上海勋和医药科技有限公司 Bet蛋白抑制剂及其应用
CN107629071B (zh) 2016-07-19 2019-12-27 上海勋和医药科技有限公司 取代2,4-(1h,3h)嘧啶二酮作为parp抑制剂及其应用
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
IL284050B2 (en) 2018-12-20 2026-01-01 Ksq Therapeutics Inc Modified pyrazolopyrimidines and modified purines and their use as 1 uso inhibitors
CN113474346B (zh) 2018-12-28 2024-12-27 福马治疗有限公司 用于抑制泛素特异性蛋白酶1的组合物

Similar Documents

Publication Publication Date Title
JP2019504821A5 (enExample)
AU2020281923B2 (en) Amino quinazoline derivatives as P2X3 inhibitors
TWI723158B (zh) 芳族磺醯胺衍生物
CN105188704B (zh) 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法
JP7736669B2 (ja) [1,2,4]トリアゾロ[1,5-c]キナゾリン-5-アミン
US10894784B2 (en) Heteroarylbenzimidazole compounds
RU2016124176A (ru) Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
US10023576B2 (en) Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
JP2018522046A5 (enExample)
EP3209664B1 (en) Bicyclic heteroaryl amine compounds as pi3k inhibitors
WO2018024602A1 (en) 2,7-diazaspiro[4.4]nonanes
JP2019519484A5 (enExample)
JP2019504821A (ja) ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン
JP2015529192A5 (enExample)
JP2012532931A5 (enExample)
US11660301B2 (en) Combination of ATR kinase inhibitors with PARP inhibitors
WO2018206547A1 (en) Combination of bub1 and atr inhibitors
US20240174683A1 (en) Map4k1 inhibitors
JPWO2021021986A5 (enExample)
JPWO2020052631A5 (enExample)
JPWO2022223750A5 (enExample)
JPWO2020086503A5 (enExample)
RU2023130418A (ru) Гетероциклические соединения
RU2021107655A (ru) Соединения триазоло-пиримидина и их применение
RU2021129724A (ru) Ингибиторы белковых тирозинфосфатаз и способы их применения